(10.02.2021)
AstraZeneca subcontracted the plant — previously owned by Novasep — to produce the drug substance of its vaccine. Volanti would not say how many doses the plant was contracted to provide. He said the plant sends its drug substance to an Italian company to be put into vials and packaged for distribution.
AstraZeneca declined to comment on Thermo Fisher’s remarks, according to Reuters.
Die EU sieht das anders: Man habe dem Unternehmen einen Vorschuss gewährt, um auf Halde zu produzieren. Vor der erwarteten Zulassung des Impfstoffs am Freitag durch die Europäische Arzneimittelbehörde hätte AstraZeneca also längst Impfdosen zurückstellen müssen. Stattdessen habe das Unternehmen die für Europa bestimmten Ampullen nach Großbritannien ausgeliefert.
The Novasep’s factory in the town of Seneffe is part of the European production chain for the Oxford-AstraZeneca coronavirus vaccine.
Beamte der belgischen Arzneimittelbehörde statteten dem AstraZeneca-Standort in Seneffe einen Besuch ab. Die EU-Kommission hatte die Untersuchung angefordert. Sie will wissen, ob auf EU-Gebiet produzierte Dosen nach Großbritannien umgeleitet wurden.
(15.06.2020)
Novasep brings to AstraZeneca more than 20 years of expertise in viral vector production. Novasep’s investment strategy in the large-scale production of biopharmaceutical products for immunotherapy and gene therapy enables Novasep to support the alliance for the production of the vaccine active substance in Europe.
The production operations will be carried out at Novasep‘s Belgian site in Seneffe. Furthermore, the biopharmaceutical ecosystem in the region allows Novasep to rapidly mobilize the additional human resources needed to achieve this project.
The @EU_Commission will continue to insist with @AstraZeneca on measures to increase predictability and stability of deliveries, and acceleration of the distribution of doses/3.
The company was expected to deliver around 80 million doses to the 27 EU countries by the end of March, an EU official told the agency.
However, it now expects that to be cut to 31 million doses due to „production problems“ at a vaccine factory in Belgium run by its partner Novasep.